JP2002530353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002530353A5 JP2002530353A5 JP2000583560A JP2000583560A JP2002530353A5 JP 2002530353 A5 JP2002530353 A5 JP 2002530353A5 JP 2000583560 A JP2000583560 A JP 2000583560A JP 2000583560 A JP2000583560 A JP 2000583560A JP 2002530353 A5 JP2002530353 A5 JP 2002530353A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- protein
- composition according
- administered
- active protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10915398P | 1998-11-20 | 1998-11-20 | |
| US60/109,153 | 1998-11-20 | ||
| PCT/US1999/027074 WO2000030677A1 (en) | 1998-11-20 | 1999-11-15 | Method of treating viral hemorrhagic fever |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002530353A JP2002530353A (ja) | 2002-09-17 |
| JP2002530353A5 true JP2002530353A5 (https=) | 2006-12-14 |
Family
ID=22326085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000583560A Pending JP2002530353A (ja) | 1998-11-20 | 1999-11-15 | ウイルス性出血熱の処置法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6270764B1 (https=) |
| EP (1) | EP1131091B1 (https=) |
| JP (1) | JP2002530353A (https=) |
| CN (1) | CN1326356A (https=) |
| AT (1) | ATE235915T1 (https=) |
| AU (1) | AU2149800A (https=) |
| BR (1) | BR9915460A (https=) |
| CA (1) | CA2351470A1 (https=) |
| DE (1) | DE69906568T2 (https=) |
| ES (1) | ES2195655T3 (https=) |
| IL (1) | IL142220A0 (https=) |
| WO (1) | WO2000030677A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2351470A1 (en) * | 1998-11-20 | 2000-06-02 | Charles Jack Fisher | Method of treating viral hemorrhagic fever |
| WO2002024215A2 (en) * | 2000-09-18 | 2002-03-28 | Eli Lilly And Company | Method for using activated protein c for the treatment of coagulation-associated disorders |
| EA200400548A1 (ru) | 2001-10-15 | 2005-06-30 | Чирон Корпорейшн | Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi) |
| US7132398B2 (en) | 2003-05-06 | 2006-11-07 | Dendreon Corporation | Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor |
| EP1729791A2 (en) * | 2004-03-17 | 2006-12-13 | Chiron Corporation | Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi) |
| WO2007092607A2 (en) * | 2006-02-09 | 2007-08-16 | Genetech, Inc. | Treatment of hemorrhagic viral infections using a tissue factor inhibitor |
| RU2379034C1 (ru) * | 2008-11-17 | 2010-01-20 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Способ лечения геморрагической лихорадки с почечным синдромом |
| EP3551198B1 (en) * | 2016-12-08 | 2022-02-02 | Cellphire Inc. | Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia |
| CA3121200A1 (en) | 2018-11-30 | 2020-06-04 | Cellphire, Inc. | Platelets as delivery agents |
| WO2020112963A1 (en) | 2018-11-30 | 2020-06-04 | Cellphire, Inc. | Platelets as delivery agents |
| IL322149A (en) | 2019-05-03 | 2025-09-01 | Cellphire Inc | Materials and methods for manufacturing blood products |
| CN114450066A (zh) | 2019-08-16 | 2022-05-06 | 塞尔菲乐有限公司 | 作为抗血小板剂逆转剂的血栓小体 |
| CA3170196A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Anti-fibrinolytic loaded platelets |
| TW202245814A (zh) | 2021-02-17 | 2022-12-01 | 美商賽菲爾公司 | 用於治療抗血小板誘導的凝血病之凍乾血小板衍生物組成物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US5550036A (en) | 1986-04-09 | 1996-08-27 | Eli Lilly And Company | Method for co-amplification of human protein C genes in human cells |
| US4992373A (en) | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
| US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| IL97312A (en) | 1990-02-23 | 1999-01-26 | Lilly Co Eli | A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient |
| US5506134A (en) * | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| AT402262B (de) | 1991-06-20 | 1997-03-25 | Immuno Ag | Arzneimittel enthaltend aktiviertes protein c |
| MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| WO1997020043A1 (en) | 1995-11-30 | 1997-06-05 | Zymogenetics, Inc. | Protein c production in transgenic animals |
| CZ298429B6 (cs) * | 1997-04-28 | 2007-10-03 | Eli Lilly And Company | Stabilní lyofilizovaný prostredek |
| CA2351470A1 (en) * | 1998-11-20 | 2000-06-02 | Charles Jack Fisher | Method of treating viral hemorrhagic fever |
| EP1090130A1 (en) * | 1999-04-30 | 2001-04-11 | Eli Lilly And Company | Protein c derivatives |
-
1999
- 1999-11-15 CA CA002351470A patent/CA2351470A1/en not_active Abandoned
- 1999-11-15 ES ES99965808T patent/ES2195655T3/es not_active Expired - Lifetime
- 1999-11-15 WO PCT/US1999/027074 patent/WO2000030677A1/en not_active Ceased
- 1999-11-15 BR BR9915460-9A patent/BR9915460A/pt not_active Application Discontinuation
- 1999-11-15 CN CN99813313A patent/CN1326356A/zh active Pending
- 1999-11-15 AU AU21498/00A patent/AU2149800A/en not_active Abandoned
- 1999-11-15 AT AT99965808T patent/ATE235915T1/de not_active IP Right Cessation
- 1999-11-15 DE DE69906568T patent/DE69906568T2/de not_active Expired - Lifetime
- 1999-11-15 JP JP2000583560A patent/JP2002530353A/ja active Pending
- 1999-11-15 IL IL14222099A patent/IL142220A0/xx unknown
- 1999-11-15 EP EP99965808A patent/EP1131091B1/en not_active Expired - Lifetime
- 1999-11-19 US US09/444,479 patent/US6270764B1/en not_active Expired - Fee Related
-
2001
- 2001-04-25 US US09/842,337 patent/US6767539B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003520822A5 (https=) | ||
| CA2066403A1 (en) | Transmucosal dosage form | |
| JP2005520778A5 (https=) | ||
| JP2002511385A5 (https=) | ||
| JP2002530353A5 (https=) | ||
| JP2007514750A5 (https=) | ||
| JP2005515966A5 (https=) | ||
| CA2186126A1 (en) | Pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration of factor viii or factor ix | |
| JP2005501110A5 (https=) | ||
| JP2002528502A5 (https=) | ||
| JPH0637395B2 (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| JP2004537500A5 (https=) | ||
| JP2002523437A5 (https=) | ||
| RU2004114865A (ru) | Композиция и способ лечения диабета | |
| JP2003514025A5 (https=) | ||
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| WO2001012214A3 (en) | MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a) | |
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| WO1990004977A3 (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| JP2002529515A5 (https=) | ||
| WO2002058720A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| WO2000013701A3 (en) | Angiogenically effective unit dose of fgf-2 and method of use | |
| Wiklund et al. | Rigidity and pulmonary edema after Innovar in a patient on levodopa therapy: report of a case |